{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-266867","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.156667+00:00","generated_at":"2026-05-17T00:19:21.458867+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Dianthus reports Q3 net loss $36.8M; gMG Ph2 data positive, CIDP Ph3 interim accelerated to Q2'26","bullets":["Net loss of $36.8M ($0.97/share) vs $25.2M ($0.74/share) Q3'24; R&D $32.5M on higher clinical costs.","Phase 2 MaGic trial of claseprubart in gMG met endpoints with stat sig MG-ADL and QMG improvements at Week 13.","CIDP Phase 3 CAPTIVATE trial interim responder analysis accelerated to Q2'26 (from 2H'26) due to faster enrollment.","In-licensed DNTH212 (bifunctional BDCA2/BAFF-APRIL inhibitor) from Leads Biolabs; Ph1 healthy volunteer data expected 2H'26.","Adjusted cash ~$525M after $30M DNTH212 milestone payments; runway into 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-266867","json":"https://secwatch.observer/filing/0001193125-25-266867.json","markdown":"https://secwatch.observer/filing/0001193125-25-266867.md","text":"https://secwatch.observer/filing/0001193125-25-266867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312525266867/0001193125-25-266867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312525266867/dnth-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:19:21.458867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}